Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
*Your Infinity Health partners with Open Loop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s
Often, specialty supplementation can offer meaningful relief and support by providing products such as those containing creatine, protein and polyunsaturated fatty acids to help preserve muscle mass [7], collagen supplements to help maintain skin elasticity, and biotin, iron and vitamin D supplements to help promote hair growth [7]
While both forms of the medication contain the same active ingredient, the injectable form of Wegovy is more effective in achieving significant weight loss
it should not be treated as automatically sustained-release